Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
14/06/2024 | 20:47 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
14/06/2024 | 17:00 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
14/06/2024 | 15:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
06/06/2024 | 14:30 | GlobeNewswire Inc. | Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
03/06/2024 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
09/05/2024 | 14:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
08/05/2024 | 15:25 | GlobeNewswire Inc. | LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
24/04/2024 | 21:25 | AllPennyStocks.com | Mixed Shelf Filing Gives Micro Cap Delayed Boost | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
27/03/2024 | 20:35 | AllPennyStocks.com | Biotech Steals The Show Following Pre-Clinical Data Announcement | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
27/03/2024 | 13:30 | GlobeNewswire Inc. | NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
21/03/2024 | 13:30 | GlobeNewswire Inc. | LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
27/02/2024 | 14:30 | GlobeNewswire Inc. | Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
26/02/2024 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
29/01/2024 | 14:30 | GlobeNewswire Inc. | First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
13/11/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
16/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
09/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
26/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Appoints Bas van der Baan as President and Chief Executive Officer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
20/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
20/07/2023 | 22:05 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
18/07/2023 | 14:00 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
17/07/2023 | 14:30 | GlobeNewswire Inc. | Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
01/12/2020 | 18:30 | GlobeNewswire Inc. | Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
30/11/2020 | 21:52 | Business Wire | WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc.... | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |